-
Adherence to Wegovy far outpaces older weight loss drugs: Cleveland Clinic study
Patients taking Novo Nordisk's weight loss drug Wegovy in 2021 and 2022 were three times more likely to continue taking the medication a year later compared to older weight loss therapies, according to a study published Dec. 6 in Obesity. -
How 2 pharmacy leaders became hospital CEOs
As more systems create a C-suite role for pharmacy leaders, health systems and hospitals are increasingly promoting these executives to non-pharmacy roles, such as CEO. -
Eli Lilly obesity drug hits pharmacy shelves
Zepbound, a newly approved obesity drug from Eli Lilly, hit the market Dec. 5. -
The Mark Cuban effect on drug pricing
In January 2022, entrepreneur and "Shark Tank" star Mark Cuban launched an online pharmacy that priced 100 medications by their manufacturing fee, a 15% markup, and a shipping and handling fee. Less than two years later, Express Scripts and CVS are following suit. -
Most of ChatGPT's answers to drug questions are wrong: Study
Nearly 75% of ChatGPT's answers to drug-related questions are incomplete or wrong, according to a study conducted at Brookville, N.Y.-based Long Island University. -
3 patients die in cancer drug trial
Three patients reportedly died in a Merus clinical trial of a new lung cancer treatment. -
Elevance to launch digital pharmacy under Carelon
Elevance Health is launching CarelonRx Pharmacy, a digital and home delivery pharmacy subsidiary, in 2024. -
Cancer society urges lawmakers to resolve drug shortages
With 16 ongoing oncology drug shortages disrupting patient care, a cancer society is asking lawmakers to push legislation aimed at systemic fixes to drug shortages. -
CVS to revamp drug pricing model
CVS Pharmacy is taking a cue from Mark Cuban Cost Plus Drugs and will launch a pharmacy reimbursement model built around a drug's cost, a pharmacy services fee and a set markup. -
Why non-union pharmacists are protesting
A tectonic shift in mindsets is inciting non-union pharmacists and other healthcare workers to protest, The New York Times reported Dec. 4. -
After cyberattack, patients struggle to fill scripts
Patients of Lovelace Health System say they can't refill their prescriptions as the Albuquerque, N.M.-based system recovers from a cyberattack, Albuquerque Journal reported Dec. 1. -
Lawmakers probe FDA's decongestant decision
House Republicans are investigating the FDA's regulation of a common decongestant found in over-the-counter cold medicines that the agency recently determined to be ineffective, The Hill reported Dec. 4. -
Eli Lilly drug gets new approval for blood cancer
The FDA has granted approval to Eli Lilly and Company's drug Jaypirca, a therapy to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. -
ASHP: What pharmacy leaders should know heading into 2024
More than three-fourths of hospital pharmacy leaders think health systems will cut service lines because of the rising cost and complexity of new drugs, according to a report released Dec. 4. -
Former Allied Health pharmacy transfers to WVU Hospitals ownership
Morgantown, W.Va.-based WVU Medicine will operate a specialty pharmacy that is currently operated by Allied Health Services, WVU Medicine's for-profit organization. -
AbbVie eyes commercial ovarian cancer market with ImmunoGen deal
Pharmaceutical giant AbbVie announced plans to acquire antibody-drug conjugate maker ImmunoGen to expand its oncology portfolio and enter the commercial market for ovarian cancer. -
Pfizer cancels weight loss drug candidate
Pfizer's weight loss drug candidate, danuglipron, helped patients shed between 4.8% and 13% body weight in a clinical trial involving patients with and without obesity, but the drugmaker is canceling research after more than half stopped taking the drug. -
Walgreens launches prescription pricing tool
Walgreens rolled out its new Rx Savings Finder on Nov. 30, a free tool offering discount cards for thousands of medications. -
3 drugs nearing approval to know: Optum
Optum Rx, a subsidiary of UnitedHealth Group, is keeping close tabs on three drug candidates that might be approved in the next few months, according to its fall 2023 report. -
FDA again warns drug facility where workers poured acid on quality data
The FDA sent another warning to an Intas Pharmaceuticals plant in India, where investigators imposed import bans in late 2022 after finding shredded quality control documents doused in acid.
Page 36 of 50